GlassScriptPhysician profile
Benjamin N Potkin
NPI 1740335090
$34,687.28
in general payments reported to CMS, 2019-2025
30 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $7,200 · 2021: $5,272 · 2022: $2,087 · 2023: $2,374 · 2024: $2,351 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,430 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,429.77 |
| Education | $141.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20,225.27 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $1,897.71 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $1,724.58 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $1,159.89 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,044.95 | 2019-2025 | Farxiga, Brilinta |
| Abbott Laboratories | $975.81 | 2020-2024 | Accent, Jot Dx, Aveir |
| Boston Scientific Corporation | $966.42 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Merck Sharp & Dohme LLC | $921.62 | 2021-2025 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $898.91 | 2019-2025 | |
| Biotronik INC. | $805.22 | 2021-2025 | Amvia Edge, Biomonitor, Edora 8 Dr-T |
| Pfizer INC. | $785.70 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $763.18 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $621.69 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $531.94 | 2019-2025 | Opsumit, Uptravi |
| Medtronic Vascular, INC. | $375.58 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $174.09 | 2021 | |
| Sanofi-Aventis U.S. LLC | $166.42 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $141.34 | 2024 | Arcalyst |
| Portola Pharmaceuticals, LLC | $124.97 | 2019 | |
| Cleerly, INC. | $101.14 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kiniksa Pharmaceuticals, LTD. | $45.66 | 2021-2022 | |
| Lundbeck LLC | $43.70 | 2019 | |
| Janssen Scientific Affairs, LLC | $40.95 | 2019 | |
| Octapharma USA, INC. | $37.50 | 2025 | Fibryga |
| Kestra Medical Technology Services, INC. | $22.55 | 2023 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $21.24 | 2022 | |
| Heartflow, INC. | $20.80 | 2025 | |
| Medtronic, INC. | $18.32 | 2022 | |
| Gilead Sciences, INC. | $15.66 | 2019 | |
| Allergan, INC. | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Potkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.